Advanced Regenerative Drainage and Immunomodulatory Protocol for Dermal Filler-Induced Skin Necrosis: A Prospective Clinical Case Series.

[BACKGROUND] The widespread use of hyaluronic acid (HA) dermal fillers has been accompanied by an increase in vascular complications, including ischemia and cutaneous necrosis. Although uncommon, filler-induced vascular compromise represents one of the most severe adverse events in aesthetic medicine and requires immediate recognition and intervention. Conventional management strategies based primarily on hyaluronidase may be insufficient in advanced ischemic stages, where inflammatory amplification and microvascular dysfunction contribute to progressive tissue injury.

[OBJECTIVE] To evaluate the clinical outcomes of the Advanced Regenerative and Immunomodulatory Drainage Protocol (ARDIP), a multimodal therapeutic approach designed to restore tissue perfusion, reduce inflammatory burden, and promote regenerative healing in patients with facial skin necrosis secondary to hyaluronic acid dermal fillers.

[METHODS] A prospective, non-randomized interventional case series was conducted including 20 patients presenting with vascular occlusion (VO) and cutaneous necrosis following hyaluronic acid injections. Lesions were classified according to a staged ischemic progression system (VO Stages III-Vb). All patients were treated using the ARDIP, which integrates high-dose hyaluronidase reperfusion, topical fibrinolytic therapy, controlled mechanical drainage through micropuncture techniques, and stage-adjusted systemic and regenerative adjuvant therapies. Clinical outcomes were assessed through standardized photographic documentation, healing time, and the Global Aesthetic Improvement Scale (GAIS).

[RESULTS] All patients completed treatment and follow-up. Complete tissue recovery without visible scarring was achieved in 95% of cases. Mean healing time was 15 ± 2.6 days, with faster recovery in early stages. The mean GAIS score was 1.05 ± 0.22, indicating exceptional aesthetic improvement. No systemic or local adverse events were observed.

[CONCLUSIONS] ARDIP appears to be a safe and effective multimodal strategy for the management of filler-induced skin necrosis, addressing both mechanical vascular obstruction and the associated inflammatory cascade.